James W Vardiman
Affiliation: University of Chicago
- Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentaryJohn M Bennett
Blood 99:3074-5. 2002
- Myelodysplastic/myeloproliferative neoplasmsElizabeth Hyjek
Department of Pathology, Hematopathology Section, University of Chicago, Chicago, Illinois, USA
Semin Diagn Pathol 28:283-97. 2011..In this review we will give an overview of these neoplasms and focus on adult MDS/MPN, especially CMML. We will give only brief updates for aCML and RARS-T; JMML will be discussed in a separate article...
- The World Health Organization (WHO) classification of the myeloid neoplasmsJames W Vardiman
Department of Pathology, University of Chicago, IL 60637, USA
Blood 100:2292-302. 2002....
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesJames W Vardiman
Department of Pathology, University of Chicago, IL, USA
Blood 114:937-51. 2009....
- Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Wendy Stock
University of Chicago, Illinois, USA
Cancer 119:90-8. 2013....
- The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasmsJames W Vardiman
University of Chicago Medical Center, 5841 South Maryland Avenue, MC0008, Chicago, IL 60637, United States
Chem Biol Interact 184:16-20. 2010....
- Myelodysplastic/myeloproliferative diseasesJames W Vardiman
University of Chicago, Department of Pathology, Chicago, Illinois, USA
Cancer Treat Res 121:13-43. 2004
- What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studiesWendy Stock
Section of Hematology Oncology, Department of Medicine, University of Chicago and University of Chicago Cancer Research Center, IL 60637, USA
Blood 112:1646-54. 2008..Based on these observations, a prospective study for AYAs with ALL using the more successful approach of the CCG has been initiated...
- Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevantZeba N Singh
Section of Hematopathology, Department of Pathology, University of Chicago, Chicago, IL 60637, USA
Am J Clin Pathol 127:197-205. 2007..We found only a borderline difference in median survival of patients with an initial t-MDS diagnosis compared with patients with an initial t-AML diagnosis...
- The new World Health Organization classification of myeloid neoplasms: Q&A with James W. Vardiman, MDJames W Vardiman
Department of Pathology, University of Chicago, Illinois, USA
Clin Adv Hematol Oncol 1:18, 21. 2003
- Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseasesJames W Vardiman
Department of Pathology, University of Chicago, Chicago, IL 60637, USA
Semin Diagn Pathol 20:154-79. 2003..It is hoped that when an excellent specimen is available, the guidelines contained in this article may provide the pathologist with assistance in arriving at the most appropriate diagnosis...
- The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cellsOzden Ozer
Section of Hematopathology, Department of Pathology, The University of Chicago, Chicago, IL 60637, USA
Leuk Lymphoma 49:1567-77. 2008..Our discovery of novel KIT transcripts underscores the importance of analysing entire protein encoding regions when studying genes of interest...
- Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago seriesSonali M Smith
Section of Hematology Oncology, Department of Medicine, MC2115, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
Blood 102:43-52. 2003..0001). Median survival time after diagnosis of t-MDS/t-AML was 8 months; survival at 5 years was less than 10%. These data confirm and extend previous associations between clinical, morphologic, and cytogenetic findings in t-MDS/t-AML...
- Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropeniaDaniel C Link
Division of Oncology, Department of Medicine, Washington University, St Louis, MO 63110, USA
Blood 110:1648-55. 2007..These data support the hypothesis that mutations of CSF3R may provide the "activated tyrosine kinase signal" that is thought to be important for leukemogenesis...
- Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panelAyalew Tefferi
Mayo Clinic, Rochester, MN 55905, USA
Blood 110:1092-7. 2007....
- The diagnostic interface between histology and molecular tests in myeloproliferative disordersAyalew Tefferi
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
Curr Opin Hematol 14:115-22. 2007..This review discusses how this process is unfolding in myeloproliferative disorders...